Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702457 | 1.00 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL3810559 | 0.97 | — | — | |
| SCHEMBL16203347 | 0.97 | CXCR4 (0.42) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL16232821 | 0.94 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL3107792 | 0.92 | CXCR4 (0.52) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL272114 | 0.91 | — | — | |
| SCHEMBL40173 | 0.91 | — | — | |
| SCHEMBL2772577 | 0.91 | CXCR4 (0.44) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL17519525 | 0.91 | ALDH1A1 (0.44) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 | |
| SCHEMBL18106209 | 0.91 | CXCR4 (0.53) | CXCR4SMN1; SMN2ALDH1A1MEN1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315511-B2 | Methods for preparing functional tetraazacycloalkane compounds using a specific cyclic bisaminal compound | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2016-04-19 | — | — | US | disclosed |
| US-20140323717-A1 | Methods for Preparing Functional Tetraazacycloalkane Compounds using a Specific Cyclic Bisaminal Compound | CNRS-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-10-30 | — | — | US | disclosed |
| EP-0022519-B1 | PROCESS FOR THE PREPARATION OF A MIXTURE OF 2-HYDROXY AND 4-HYDROXY BENZYL ALCOHOL | BAYER AG (DE) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323717-A1 | Methods for Preparing Functional Tetraazacycloalkane Compounds using a Specific Cyclic Bisaminal Compound | NISCH, FHIT, FLNB | CXCR4 1404/4885SMN1; SMN2 1463/4885ALDH1A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.